Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares

Plus: MeiraGTx, scPharmaceuticals each raise $50M

BioCentury’s roundup of translational innovations

With an £80M series B, University of Oxford spinout is targeting immune suppressive signaling networks in autoimmune diseases

Development programs similar to Tyvyt’s could be at risk, but some Chinese PD-1s could pass muster with FDA

Immune system biomarkers take center stage among emerging targets at ASH 2019

How Cell Design rewires T cell therapies for local action in multiple diseases

Courting combinations with PD-1